However, clinical translation confronts substantial challenges: the lack of dynamic monitoring data on iron metabolism (serum ferritin), oxidative stress (ROS levels), and immune markers (IL-1β concentration) in DKD patients hampers the establishment of clear biomarker thresholds to guide effective drug intervention. This evidence concerns the gene IL1B and diabetic kidney disease.